UB Paderborn / Katalog / Suche / in CDI

Molecular mechanism of phosphopeptide neoantigen immunogenicity

Nature communications, 2023-06, Vol.14 (1), p.3763-3763, Article 3763

2023

Volltextzugriff (PDF)

Author Correction: Molecular mechanism of phosphopeptide neoantigen immunogenicity

Nature communications, 2023-07, Vol.14 (1), p.4522-1, Article 4522

2023

Volltextzugriff (PDF)

Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3819-3819

2018

Volltextzugriff (PDF)

Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea racemosa

ACS chemical neuroscience, 2012-11, Vol.3 (11), p.941-951

2012

Volltextzugriff (PDF)

Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture

iScience, 2024-03, Vol.27 (3), p.109006-109006, Article 109006

2024

Volltextzugriff (PDF)

377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A229-A230

2020

Volltextzugriff (PDF)

Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization

Biochemistry (Easton), 1999-05, Vol.38 (21), p.6791-6800

1999

Volltextzugriff (PDF)

Multikilogram-Scale Production of Cycloartenol Triterpenoid Glycosides as Synthetic Intermediates for a γ‑Secretase Modulator

Organic process research & development, 2014-06, Vol.18 (6), p.676-682

2014

Volltextzugriff (PDF)

Natural Product and Natural Product-Derived Gamma Secretase Modulators from Actaea Racemosa Extracts

Medicines (Basel, Switzerland), 2015-06, Vol.2 (3), p.127-140

2015

Volltextzugriff (PDF)

Initial Optimization of a New Series of γ‑Secretase Modulators Derived from a Triterpene Glycoside

ACS medicinal chemistry letters, 2012-11, Vol.3 (11), p.908-913

2012

Volltextzugriff (PDF)

SAR investigations on a novel class of gamma-secretase modulators based on a unique scaffold

MedChemComm, 2013-03, Vol.4 (3), p.569-574

2013

Volltextzugriff (PDF)

Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization

BBA - Molecular Basis of Disease, 2000-07, Vol.1502 (1), p.76-84

Findeis, Mark A.

2000

Volltextzugriff (PDF)

AGEN2373 is a conditionally-active agonist antibody targeting the costimulatory receptor CD137 for the treatment of human malignancies

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14005-e14005

2019

Volltextzugriff (PDF)

Abstract 3825: INCAGN02390, a novel antagonist antibody that targets the co-inhibitory receptor TIM-3

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3825-3825

2018

Volltextzugriff (PDF)

Targeted Delivery of DNA Using YEE(GalNAcAH)3, a Synthetic Glycopeptide Ligand for the Asialoglycoprotein Receptor

Bioconjugate chemistry, 1994-11, Vol.5 (6), p.612-620

1994

Volltextzugriff (PDF)

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

Blood, 2017-12, Vol.130, p.1868-1868

2017

Volltextzugriff (PDF)

Abstract 4609: Agenus’ next generation cancer vaccine platforms

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4609-4609

2017

Volltextzugriff (PDF)

Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3654-3654

2017

Volltextzugriff (PDF)

Peptide and Protein Synthesis by Segment Synthesis-Condensation

Science (American Association for the Advancement of Science), 1989-01, Vol.243 (4888), p.187-192

1989

Volltextzugriff (PDF)

Abstract A037: The Agenus Immunogenic Mutation platform (AIM™) generates synthesis-ready blueprints for the AutoSynVax™ vaccine patient-specific neo-antigen vaccine

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.A037-A037

2016

Volltextzugriff (PDF)

Preparation of Asialoorosomucoid-Polylysine Conjugates

Bioconjugate chemistry, 1994-07, Vol.5 (4), p.306-311

1994

Volltextzugriff (PDF)

Fumarase-catalyzed synthesis of L-threo-chloromalic acid and its conversion to 2-deoxy-D-ribose and D-erythro-sphingosine

Journal of organic chemistry, 1987-06, Vol.52 (13), p.2838-2848

1987

Volltextzugriff (PDF)

Chemistry and Biology of Amyloid Inhibition

Protein Misfolding Diseases, 2010, p.903-915

2010

Volltextzugriff (PDF)

Nitrobenzophenone oxime based resins for the solid-phase synthesis of protected peptide segments

Journal of organic chemistry, 1989-07, Vol.54 (14), p.3478-3482

1989

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Molecular mechanism of phosphopeptide neoantigen immunogenicity

Author Correction: Molecular mechanism of phosphopeptide neoantigen immunogenicity

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies

Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea racemosa

Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture

377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization

Multikilogram-Scale Production of Cycloartenol Triterpenoid Glycosides as Synthetic Intermediates for a γ‑Secretase Modulator

Natural Product and Natural Product-Derived Gamma Secretase Modulators from Actaea Racemosa Extracts

Initial Optimization of a New Series of γ‑Secretase Modulators Derived from a Triterpene Glycoside

SAR investigations on a novel class of gamma-secretase modulators based on a unique scaffold

Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization

AGEN2373 is a conditionally-active agonist antibody targeting the costimulatory receptor CD137 for the treatment of human malignancies

Abstract 3825: INCAGN02390, a novel antagonist antibody that targets the co-inhibitory receptor TIM-3

Targeted Delivery of DNA Using YEE(GalNAcAH)3, a Synthetic Glycopeptide Ligand for the Asialoglycoprotein Receptor

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

Abstract 4609: Agenus’ next generation cancer vaccine platforms

Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model

Peptide and Protein Synthesis by Segment Synthesis-Condensation

Abstract A037: The Agenus Immunogenic Mutation platform (AIM™) generates synthesis-ready blueprints for the AutoSynVax™ vaccine patient-specific neo-antigen vaccine

Preparation of Asialoorosomucoid-Polylysine Conjugates

Fumarase-catalyzed synthesis of L-threo-chloromalic acid and its conversion to 2-deoxy-D-ribose and D-erythro-sphingosine

Chemistry and Biology of Amyloid Inhibition

Nitrobenzophenone oxime based resins for the solid-phase synthesis of protected peptide segments

Suchergebnisse filtern